• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 57-48-7 Price $30 / 20mg
    Catalog No.CFN98121Purity>=98%
    Molecular Weight180.16Type of CompoundMiscellaneous
    FormulaC6H12O6Physical DescriptionWhite cryst.
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Periyar University (India)
  • Chiang Mai University (Thailand)
  • Sanford Burnham Prebys Medical D... (USA)
  • University of Perugia (Italy)
  • Pennsylvania State University (USA)
  • National Hellenic Research Found... (Greece)
  • Medical University of Gdansk (Poland)
  • Universidade do Porto (Portugal)
  • Heinrich-Heine-University Düsse... (Germany)
  • University of Illinois at Chicago (USA)
  • Instituto de Investigaciones Agr... (Chile)
  • More...
  • Package
    Featured Products
    3-O-Feruloylquinic acid

    Catalog No: CFN92393
    CAS No: 1899-29-2
    Price: $488/5mg

    Catalog No: CFN99773
    CAS No: 604-80-8
    Price: $188/20mg

    Catalog No: CFN96169
    CAS No: 20013-75-6
    Price: $388/20mg
    Ganoderiol F

    Catalog No: CFN99244
    CAS No: 114567-47-4
    Price: $398/5mg
    Cryptochlorogenic acid

    Catalog No: CFN99117
    CAS No: 905-99-7
    Price: $128/20mg
    Biological Activity
    Description: Fructose is a simple ketonic monosaccharide found in many plants. Dietary fructose can specifically increase hepatic de novo lipogenesis (DNL), promote dyslipidemia, decreases insulin sensitivity, and increase visceral adiposity in overweight/obese adults; it also can reduce circulating insulin and leptin, attenuate postprandial suppression of ghrelin, and increase triglycerides in women.
    Targets: Glut | LDL
    In vitro:
    Am J Clin Nutr. 2002 Nov;76(5):911-22.
    Fructose, weight gain, and the insulin resistance syndrome.[Pubmed: 12399260]
    This review explores whether Fructose consumption might be a contributing factor to the development of obesity and the accompanying metabolic abnormalities observed in the insulin resistance syndrome.
    The per capita disappearance data for Fructose from the combined consumption of sucrose and high-Fructose corn syrup have increased by 26%, from 64 g/d in 1970 to 81 g/d in 1997. Both plasma insulin and leptin act in the central nervous system in the long-term regulation of energy homeostasis. Because Fructose does not stimulate insulin secretion from pancreatic beta cells, the consumption of foods and beverages containing Fructose produces smaller postprandial insulin excursions than does consumption of glucose-containing carbohydrate. Because leptin production is regulated by insulin responses to meals, Fructose consumption also reduces circulating leptin concentrations. The combined effects of lowered circulating leptin and insulin in individuals who consume diets that are high in dietary Fructose could therefore increase the likelihood of weight gain and its associated metabolic sequelae. In addition, Fructose, compared with glucose, is preferentially metabolized to lipid in the liver. Fructose consumption induces insulin resistance, impaired glucose tolerance, hyperinsulinemia, hypertriacylglycerolemia, and hypertension in animal models. The data in humans are less clear.
    Although there are existing data on the metabolic and endocrine effects of dietary Fructose that suggest that increased consumption of Fructose may be detrimental in terms of body weight and adiposity and the metabolic indexes associated with the insulin resistance syndrome, much more research is needed to fully understand the metabolic effect of dietary Fructose in humans.
    In vivo:
    J Neurochem. 2015 May;133(4):572-81.
    Uptake and metabolism of fructose by rat neocortical cells in vivo and by isolated nerve terminals in vitro.[Pubmed: 25708447]
    Fructose reacts spontaneously with proteins in the brain to form advanced glycation end products (AGE) that may elicit neuroinflammation and cause brain pathology, including Alzheimer's disease.
    We investigated whether Fructose is eliminated by oxidative metabolism in neocortex. Injection of [(14) C]Fructose or its AGE-prone metabolite [(14) C]glyceraldehyde into rat neocortex in vivo led to formation of (14) C-labeled alanine, glutamate, aspartate, GABA, and glutamine. In isolated neocortical nerve terminals, [(14) C]Fructose-labeled glutamate, GABA, and aspartate, indicating uptake of Fructose into nerve terminals and oxidative Fructose metabolism in these structures. This was supported by high expression of hexokinase 1, which channels Fructose into glycolysis, and whose activity was similar with Fructose or glucose as substrates. By contrast, the Fructose-specific ketohexokinase was weakly expressed. The Fructose transporter Glut5 was expressed at only 4% of the level of neuronal glucose transporter Glut3, suggesting transport across plasma membranes of brain cells as the limiting factor in removal of extracellular Fructose. The genes encoding aldose reductase and sorbitol dehydrogenase, enzymes of the polyol pathway that forms glucose from Fructose, were expressed in rat neocortex. These results point to Fructose being transported into neocortical cells, including nerve terminals, and that it is metabolized and thereby detoxified primarily through hexokinase activity. We asked how the brain handles Fructose, which may react spontaneously with proteins to form 'advanced glycation end products' and trigger inflammation. Neocortical cells took up and metabolized extracellular Fructose oxidatively in vivo, and isolated nerve terminals did so in vitro.
    The low expression of Fructose transporter Glut5 limited uptake of extracellular Fructose. Hexokinase was a main pathway for Fructose metabolism, but ketohexokinase (which leads to glyceraldehyde formation) was expressed too. Neocortical cells also took up and metabolized glyceraldehyde oxidatively.
    J Clin Endocrinol Metab. 2004 Jun;89(6):2963-72.
    Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women.[Pubmed: 15181085 ]
    Previous studies indicate that leptin secretion is regulated by insulin-mediated glucose metabolism. Because Fructose, unlike glucose, does not stimulate insulin secretion, we hypothesized that meals high in Fructose would result in lower leptin concentrations than meals containing the same amount of glucose.
    Blood samples were collected every 30-60 min for 24 h from 12 normal-weight women on 2 randomized days during which the subjects consumed three meals containing 55, 30, and 15% of total kilocalories as carbohydrate, fat, and protein, respectively, with 30% of kilocalories as either a Fructose-sweetened [high Fructose (HFr)] or glucose-sweetened [high glucose (HGl)] beverage. Meals were isocaloric in the two treatments. Postprandial glycemic excursions were reduced by 66 +/- 12%, and insulin responses were 65 +/- 5% lower (both P < 0.001) during HFr consumption. The area under the curve for leptin during the first 12 h (-33 +/- 7%; P < 0.005), the entire 24 h (-21 +/- 8%; P < 0.02), and the diurnal amplitude (peak - nadir) (24 +/- 6%; P < 0.0025) were reduced on the HFr day compared with the HGl day. In addition, circulating levels of the orexigenic gastroenteric hormone, ghrelin, were suppressed by approximately 30% 1-2 h after ingestion of each HGl meal (P < 0.01), but postprandial suppression of ghrelin was significantly less pronounced after HFr meals (P < 0.05 vs. HGl). Consumption of HFr meals produced a rapid and prolonged elevation of plasma triglycerides compared with the HGl day (P < 0.005).
    Because insulin and leptin, and possibly ghrelin, function as key signals to the central nervous system in the long-term regulation of energy balance, decreases of circulating insulin and leptin and increased ghrelin concentrations, as demonstrated in this study, could lead to increased caloric intake and ultimately contribute to weight gain and obesity during chronic consumption of diets high in Fructose.
    J. Clin. Invest., 2009, 119(5):1322-34.
    Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.[Pubmed: 19381015 ]
    Studies in animals have documented that, compared with glucose, dietary Fructose induces dyslipidemia and insulin resistance.
    To assess the relative effects of these dietary sugars during sustained consumption in humans, overweight and obese subjects consumed glucose- or Fructose-sweetened beverages providing 25% of energy requirements for 10 weeks. Although both groups exhibited similar weight gain during the intervention, visceral adipose volume was significantly increased only in subjects consuming Fructose. Fasting plasma triglyceride concentrations increased by approximately 10% during 10 weeks of glucose consumption but not after Fructose consumption. In contrast, hepatic de novo lipogenesis (DNL) and the 23-hour postprandial triglyceride AUC were increased specifically during Fructose consumption. Similarly, markers of altered lipid metabolism and lipoprotein remodeling, including fasting apoB, LDL, small dense LDL, oxidized LDL, and postprandial concentrations of remnant-like particle-triglyceride and -cholesterol significantly increased during Fructose but not glucose consumption. In addition, fasting plasma glucose and insulin levels increased and insulin sensitivity decreased in subjects consuming Fructose but not in those consuming glucose.
    These data suggest that dietary Fructose specifically increases DNL, promotes dyslipidemia, decreases insulin sensitivity, and increases visceral adiposity in overweight/obese adults.
    Fructose Description
    Source: The leaves of Ginkgo biloba L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Lappaol C

    Catalog No: CFN95068
    CAS No: 64855-00-1
    Price: $333/10mg

    Catalog No: CFN96248
    CAS No: 79120-40-4
    Price: $368/5mg
    Buddlenoid A

    Catalog No: CFN95025
    CAS No: 142750-32-1
    Price: $368/5mg

    Catalog No: CFN95103
    CAS No: 153127-42-5
    Price: $318/5mg

    Catalog No: CFN98400
    CAS No: 31524-62-6
    Price: $188/20mg

    Catalog No: CFN98730
    CAS No: 479-43-6
    Price: $388/5mg
    Iristectorin A

    Catalog No: CFN95037
    CAS No: 37744-61-9
    Price: $333/5mg
    Vicenin -1

    Catalog No: CFN92030
    CAS No: 35927-38-9
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 5.5506 mL 27.7531 mL 55.5062 mL 111.0124 mL 138.7655 mL
    5 mM 1.1101 mL 5.5506 mL 11.1012 mL 22.2025 mL 27.7531 mL
    10 mM 0.5551 mL 2.7753 mL 5.5506 mL 11.1012 mL 13.8766 mL
    50 mM 0.111 mL 0.5551 mL 1.1101 mL 2.2202 mL 2.7753 mL
    100 mM 0.0555 mL 0.2775 mL 0.5551 mL 1.1101 mL 1.3877 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Animal Research:
    Life Sci. 2015 Jan 15;121:40-5.
    Chronic intermittent hypobaric hypoxia ameliorates endoplasmic reticulum stress mediated liver damage induced by fructose in rats.[Pubmed: 25476828]
    High-Fructose intake induces nonalcoholic fatty liver disease (NAFLD) and chronic intermittent hypobaric hypoxia (CIHH) has beneficial effects on the body. We hypothesized that CIHH has protective effects on the impaired hepar in Fructose-fed rats.
    Sprague-Dawley rats (male, 160-180 g) were randomly divided into 4 groups: control group (CON), Fructose group (FRUC, 10% Fructose in drinking water for 6 weeks), CIHH group (simulated 5000m altitude, 6h per day for 6 weeks), and CIHH plus Fructose groups (CIHH-F). Histopathology of liver, arterial blood pressure, blood biochemicals, hepatocyte apoptosis, and marker proteins of endoplasmic reticulum stress (ERS) were measured. The arterial blood pressure, body mass index, abdominal fat weight and liver weight were increased in FRUC rats but not in CIHH-F rats. Likewise, the serum glucose, insulin, insulin C peptide, triglyceride (TG) and total cholesterol (TC) were elevated in FRUC rats but not in CIHH-F rats after fasting 12h. Meanwhile, the hepatic steatosis and hepatocyte apoptosis occurred in FRUC rats but not in CIHH-F rats. Finally the expression of ERS markers including GRP78 (glucose-regulated protein78), CHOP (C/EBP Homologous Protein), and caspase-12 in hepatic tissue were up-regulated in FRUC rats, but such up-regulation was not observed in CIHH-F rats.
    Our results suggest that CIHH protect hepar against hepatic damage through inhibition of ERS in Fructose-fed rats. CIHH might be the new therapy for NAFLD.